Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.51 |
| ▸ | MEN1 | O00255 | 9/20 | 0.51 |
| ▸ | TOP1 | P11387 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.37 |
| ▸ | MAPT | P10636 | 8/20 | 0.37 |
| ▸ | TNKS | O95271 | 6/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10811547 | 0.83 | CUL4A (0.46) | KMT2AMEN1KDM4EMAPTTNKS | |
| SCHEMBL10808336 | 0.81 | MEN1 (0.32) | KMT2AMEN1 | |
| SCHEMBL10804704 | 0.81 | MEN1 (0.33) | KMT2AMEN1KDM4EMAPTRAB9A | |
| Tetrazolast SCHEMBL635434 | 0.80 | MEN1 (0.38) | KMT2AMEN1TOP1KDM4EMAPT | |
| SCHEMBL8546887 | 0.80 | ALDH1A1 (0.38) | KMT2AMEN1KDM4EMAPTTNKS | |
| SCHEMBL10804501 | 0.78 | ALDH1A1 (0.35) | KMT2AMEN1KDM4EMAPTRAB9A | |
| SCHEMBL4489136 | 0.78 | KMT2A (0.57) | KMT2AMEN1TOP1KDM4EMAPT | |
| Tetrazolast SCHEMBL20953834 | 0.77 | MEN1 (0.50) | KMT2AMEN1TOP1KDM4EMAPT | |
| SCHEMBL10802606 | 0.76 | MAPT (0.36) | KMT2AMEN1KDM4EMAPTRAB9A | |
| SCHEMBL10598255 | 0.76 | ALDH1A1 (0.31) | ALDH1A1CUL4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743419-B1 | NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-09-14 | — | — | EP | claimed |
| EP-2913062-B1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR RETINOPATHY OF PREMATURITY AND METHOD OF TESTING FOR RETINOPATHY OF PREMATURITY | JAPAN INNOVATIVE THERAPEUTICS INC (JP) | 2019-05-08 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1668009-A1 | HCV INHIBITORS AND METHODS OF USING THEM | Rigel Pharmaceuticals, Inc. (US) | 2006-06-14 | — | — | EP | claimed |
| US-20050090521-A1 | HCV inhibitors and methods of using them | RIGEL PHARMACEUTICALS, INC. | 2005-04-28 | — | — | US | claimed |
| WO-2005030774-A1 | HCV INHIBITORS AND METHODS OF USING THEM | RIGEL PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0751945-B1 | PROCESS FOR PREPARING (1H-TETRAZOL-5-yl)TETRAZOLO 1,5-a] QUINOLINES AND NAPHTHYRIDINES | MERRELL PHARMA INC (US) | 1998-07-01 | — | — | EP | claimed |
| EP-0751945-A1 | PROCESS FOR PREPARING (1H-TETRAZOL-5-yl)TETRAZOLO 1,5-a] QUINOLINES AND NAPHTHYRIDINES | MERRELL PHARMACEUTICALS INC. (US) | 1997-01-08 | — | — | EP | claimed |
| WO-1995026348-A1 | PROCESS FOR PREPARING (1H-TETRAZOL-5-yl)TETRAZOLO [1,5-a] QUINOLINES AND NAPHTHYRIDINES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-10-05 | — | — | WO | claimed |
| EP-0120484-B1 | (1H-TETRAZOL-5-YL)TETRAZOLO (1,5-A)-QUINOLINES AND RELATED COMPOUNDS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-04-22 | — | — | EP | claimed |
| US-4496569-A | Antiallergic (1H-tetrazol-5-yl)tetrazolo[1,5-a]quinolines and derivatives thereof | THE DOW CHEMICAL COMPANY (US) | 1985-01-29 | — | — | US | claimed |
| EP-0120484-A1 | (1H-tetrazol-5-yl)tetrazolo (1,5-a)-quinolines and related compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1984-10-03 | — | — | EP | claimed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| EP-0120484-A1 | (1H-tetrazol-5-yl)tetrazolo (1,5-a)-quinolines and related compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1984-10-03 | — | — | EP | disclosed |
| EP-0120484-A1 | (1H-tetrazol-5-yl)tetrazolo (1,5-a)-quinolines and related compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1984-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090521-A1 | HCV inhibitors and methods of using them | HAVCR2, GLS2, EIF2AK2 | KMT2A 4081/4885MEN1 4880/4885TOP1 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.